Fore Capital’s Precigen PGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-341,811
Closed -$485K 68
2025
Q2
$485K Sell
341,811
-50,000
-13% -$71K 0.17% 25
2025
Q1
$584K Hold
391,811
0.35% 34
2024
Q4
$439K Buy
391,811
+85,000
+28% +$72.5K 0.17% 41
2024
Q3
$291K Buy
306,811
+100,000
+48% +$126K 0.12% 31
2024
Q2
$327K Sell
206,811
-99,980
-33% -$145K 0.21% 38
2024
Q1
$445K Sell
306,791
-50,000
-14% -$71.8K 0.27% 30
2023
Q4
$478K Sell
356,791
-70,000
-16% -$82.2K 0.23% 30
2023
Q3
$606K Sell
426,791
-63,209
-13% -$89.6K 0.27% 27
2023
Q2
$564K Hold
490,000
0.26% 23
2023
Q1
$519K Buy
490,000
+385,000
+367% +$555K 0.29% 19
2022
Q4
$160K Sell
105,000
-90,000
-46% -$155K 0.06% 32
2022
Q3
$413K Sell
195,000
-100,000
-34% -$211K 0.51% 20
2022
Q2
$395K Buy
295,000
+160,000
+119% +$237K 0.41% 25
2022
Q1
$285K Buy
+135,000
New +$329K 0.13% 41
2021
Q3
Sell
-10,000
Closed -$65K 67
2021
Q2
$65K Buy
+10,000
New +$69.9K 0.02% 58
2020
Q2
Sell
-28,050
Closed -$95K 78
2020
Q1
$95K Buy
+28,050
New +$121K 0.07% 60
2018
Q4
Sell
-10,000
Closed -$112K 74
2018
Q3
$172K Buy
+10,000
New +$149K 0.05% 52
2018
Q1
Sell
-15,000
Closed -$214K 82
2017
Q4
$173K Buy
+15,000
New +$223K 0.07% 69

Other funds holding PGEN

Fore Capital's PGEN Position: Q3 2025 in Review

Fore Capital sold out of Precigen (PGEN) in Q3 2025, closing a stake of 341,811 shares — an estimated $485K sold.

Fore Capital first reported a position in PGEN in Q4 2017 and held it in 18 quarters. The position peaked at $606K in Q3 2023. 167 funds tracked by Wall St. Rank hold PGEN as of Q3 2025.

  • Fore Capital reported no remaining Precigen position as of Q3 2025 after selling out during the quarter.
  • Fore Capital sold 341,811 Precigen shares in Q3 2025, an estimated $485K.
  • Fore Capital first reported a position in Precigen in Q4 2017 and held it in 18 quarters.
  • Fore Capital's Precigen position peaked at $606K in Q3 2023.
  • 167 funds tracked by Wall St. Rank held Precigen as of Q3 2025.

Based on Fore Capital's 13F filing for Q3 2025, filed 13 Nov 2025.